Oncolytics Biotech Inc - Company Profile
Powered by 
All the sales intelligence you need on Oncolytics Biotech Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Oncolytics Biotech Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Oncolytics Biotech Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Oncolytics Biotech Inc (Oncolytics) is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company's main activity involves the development of pelareorep, an intravenous immunotherapeutic agent derived from a non-pathogenic reovirus designed to treat solid tumors and hematological malignancies. Pelareorep, a proprietary isolate of the reovirus, is the company's major product, which aims to enhance the immune system's ability to combat cancer. This treatment activates both innate and adaptive immune systems, enhancing anti-tumor responses and increasing susceptibility to various oncology treatments. The company's products are primarily targeted at patients with cancers where existing treatments have been ineffective, with applications in various oncology treatments, including chemotherapies and immunotherapies. Oncolytics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 325, 4350 Executive Drive, San Diego, California, 92121
No of Employees
29
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ONCY (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-26.2%
(2024 vs 2023)
Market Cap*
$107.5M
* As of and is in US$
Oncolytics Biotech Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Pelareorep: Breast Cancer and Gastro-Intestinal Cancer. |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In May, the company received regulatory clearance to evaluate pelareorep in combination with modified folfirinox +/- an anti-PD-L1 inhibitor in pancreatic cancer. |
| 2022 | Regulatory Approval | In December, the company's pelareorep in combination with Roche's atezolizumab, chemotherapeutic agents gemcitabine and nab-paclitaxel received U.S.FDA fast track status for the treatment of dvanced/metastatic pancreatic ductal adenocarcinoma (PDAC). |
| 2020 | Contracts/Agreements | In October, the company collaborated with Roche and AIO to study virus-based treatment combinations for gastrointestinal cancers. |
Competitor Comparison
| Key Parameters | Oncolytics Biotech Inc | Infinity Pharmaceuticals Inc | IMV Inc | AngioChem Inc | LianBio |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Canada | Canada | United States of America |
| City | San Diego | Cambridge | Dartmouth | Westmount | Princeton |
| State/Province | California | Massachusetts | Nova Scotia | Quebec | New Jersey |
| No. of Employees | 29 | 30 | 63 | - | 163 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wayne Pisano | Chairman | Executive Board | 2025 | - |
| Jared Kelly | Chief Executive Officer; Director | Executive Board | 2025 | - |
| Kirk Look | Chief Financial Officer | Senior Management | 2012 | - |
| John McAdory | Chief Operating Officer | Senior Management | 2026 | - |
| Allison Hagerman | Vice President - Product Development; Chief Technology Officer | Senior Management | 2010 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer